Original article
Type 2 diabetes patients requiring empagliflozin in Southeast of Iran: Frequency and guideline adherence (2022–2023)
Pacientes con diabetes tipo 2 que requieren empagliflozina en el sureste de Irán: frecuencia y cumplimiento de las directrices (2022-2023)
a Gastroenterology and Hepatology Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
b Clinical Research Development Unit, Afzalipour Hospital, Kerman University of Medical Sciences, Kerman, Iran
c Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran
d Endocrinology and Metabolism Research Center, Institute of Basic and Clinical Physiology Sciences, Kerman University of Medical Sciences, Kerman, Iran
Read
356
Timeswas read the article
2
Total PDF
354
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 December | 10 | 0 | 10 |
| 2024 November | 13 | 0 | 13 |
| 2024 October | 32 | 0 | 32 |
| 2024 September | 42 | 0 | 42 |
| 2024 August | 38 | 0 | 38 |
| 2024 July | 35 | 0 | 35 |
| 2024 June | 30 | 0 | 30 |
| 2024 May | 49 | 0 | 49 |
| 2024 April | 84 | 2 | 86 |
| 2024 March | 21 | 0 | 21 |